EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness Analysis of Treatments for Children With Uncontrolled Asthma Symptoms Despite Inhaled Corticosteroids

Giovanna Culeddu iD, Sofia Cividini iD, Ian Sinha iD, Sarah Donegan iD, Katie Rose iD, Olivia Fulton, Stephen Turner iD, Catrin Tudur Smith iD, Dyfrig A Hughes iD, EINSTEIN collaborative group

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Giovanna Culeddu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Anti-Asthmatic Agents, Leukotriene Antagonists. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by NIHR HTA grant number 16/110/16..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is uncertainty about the cost‐effectiveness of treatment options for children and adolescents with uncontrolled asthma despite inhaled corticosteroid (ICS) treatment.

Methods

A Markov state‐transition model was developed to simulate costs from the perspective of the National Health Service in the UK and health outcomes associated with low, medium and high dose ICS, ICS in combination with long‐acting β 2 ‐adrenoceptor agonists (LABAs) or leukotriene receptor antagonists (LTRAs), and LTRA monotherapy. Healthcare resource use and health state utilities were identified from literature searches. Transition probabilities were derived from a systematic review and network meta‐analysis. Total costs and quality‐adjusted life years were computed, and incremental cost‐effectiveness ratios estimated over a 1‐year time horizon. Parameter, structural and probabilistic sensitivity analyses were performed.

Results

Compared with low‐dose ICS, medium‐dose ICS and ICS + LABA had incremental cost‐effectiveness ratios of £255,555 and £304,956 per quality‐adjusted life year gained, respectively. High‐dose ICS, LTRA alone and in combination with ICS were dominated by alternatives which were less costly and associated with a greater number of quality‐adjusted life years. The incremental cost‐effectiveness ratio for medium‐dose ICS reduced to £14,797 per quality‐adjusted life year gained when the transition probabilities were increased to reflect a higher risk of asthma exacerbation. ICS + LABA became cost effective with a > 60% reduction in inhaler price.

Conclusions

Treatment escalation beyond low‐dose ICS in children and adolescents with uncontrolled asthma may only be cost‐effective in the UK if the prices of alternatives reduce or treatment is targeted to those at higher risk of asthma exacerbations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAdrenal Cortex HormonesAnti-Asthmatic AgentsLeukotriene AntagonistsAdrenergic beta-2 Receptor AgonistsHumansCost-Benefit AnalysisChildAdolescentQuality-Adjusted Life YearsAdministration, InhalationMarkov ChainsUnited KingdomDrug Therapy, CombinationCost-Effectiveness Analysis

Stichwörter der Autor:innen

asthmacost‐effectivenesseconomic evaluationinhaled corticosteroidspediatric

Substanzen

Adrenal Cortex HormonesAnti-Asthmatic AgentsLeukotriene AntagonistsAdrenergic beta-2 Receptor Agonists

Autor:innen und Institutionen

  • Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
  • Institute of Population Health, Department of Health Data Science, University of Liverpool, Liverpool, England, UK.
  • Alder Hey Children's Foundation NHS Trust, Liverpool, England, UK.
  • Patient Representative, Liverpool, England, UK.
  • Women and Children Division, NHS Grampian, Aberdeen, Scotland, UK.
  • Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK.

ORCID-Profile: Giovanna Culeddu, Sofia Cividini, Ian Sinha, Sarah Donegan, Katie Rose, Stephen Turner, Catrin Tudur Smith, Dyfrig A Hughes

Förderung

  • This study was supported by NIHR HTA grant number 16/110/16.

Zitieren

APA

Culeddu, G., Cividini, S., Sinha, I., Donegan, S., Rose, K., Fulton, O., Turner, S., Smith, C. T., Hughes, D. A., & EINSTEIN collaborative group (2025). Cost‐Effectiveness Analysis of Treatments for Children With Uncontrolled Asthma Symptoms Despite Inhaled Corticosteroids. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71414

Vancouver

Culeddu G, Cividini S, Sinha I, Donegan S, Rose K, Fulton O, et al. Cost‐Effectiveness Analysis of Treatments for Children With Uncontrolled Asthma Symptoms Despite Inhaled Corticosteroids. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71414

BibTeX
@article{Culeddu2025,
  author = {Culeddu, Giovanna and Cividini, Sofia and Sinha, Ian and Donegan, Sarah and Rose, Katie and Fulton, Olivia and Turner, Stephen and Smith, Catrin Tudur and Hughes, Dyfrig A and EINSTEIN collaborative group, EINSTEIN collaborative group},
  title = {Cost‐Effectiveness Analysis of Treatments for Children With Uncontrolled Asthma Symptoms Despite Inhaled Corticosteroids},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71414}
}
Kostenlos starten →